Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
life sciences
national blog main
2
×
san francisco blog main
2
×
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boston
boston blog main
boston top stories
clinical trials
deals
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
fda
food and drug administration
gene therapy
joshua brumm
kaleido biosciences
medical device
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york blog main
pulmonary arterial hypertension
raleigh-durham blog main
rare disease drugs
romesh subramanian
san diego blog main
san francisco
san francisco top stories
startups
steadymed
susanna high
treprostinil
united therapeutics
vertex pharmaceuticals
What
drug
rare
2
×
therapeutics
ago
biotechs
building
considering
data
deal
developer
disease
diseases
dyne
early
established
expected
experimental
eyes
firm
genetic
having
humans
ipo
ipos
long
lung
medicines
momentum
muscle
pah
reach
reaches
rivalry
seller
steadymed
therapy
united
worked
Language
unset
Current search:
rare
×
biotech
×
" san francisco blog main "
×
" national blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed
